Please login to the form below

Not currently logged in
Email:
Password:

Teva/Pfizer settle Neurontin suit

Teva Pharmaceutical has announced it has settled a patent dispute with Pfizer concerning generic versions of Pfizer's Neurontin (gabapentin) – a drug marketed for pain management and the treatment of epilepsy

Teva Pharmaceutical has announced it has settled a patent dispute with Pfizer concerning generic versions of Pfizer's Neurontin (gabapentin) – a drug marketed for pain management and the treatment of epilepsy.

The Israel-based generic manufacturer said litigation related to capsules and tablets sold by the company and its subsidiary Ivax Pharmaceuticals has been 'dismissed' by United States District Court for the District of New Jersey in accordance with a settlement reached between the two parties.

Teva did not reveal financial details of the settlement, but reports have suggested it is less than $100m.

Pfizer had filed litigation claiming that Teva's generic version infringed a patent that expires in 2017, with the US-based drugmaker seeking compensation for profit lost due to competition.

A generic gabapentin was launched by Ivax in 2004. Teva later purchased Ivax in 2006.

1st June 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Peter Jackson
Rethinking our approach to infectious disease preparedness
The importance of long-term strategic investment to prepare for the next threat that emerges...
New from the PhRMA: Diversity in clinical trials principles summarised
In November 2020, PhRMA announced the first-ever, industry-wide principles on clinical trial diversity. The principles were approved by the PhRMA Boards of Directors and will take effect in April 2021....
New from the FDA: Diversity in clinical trials guidance summarised
In November 2020, the FDA released guidance to enable greater diversity in clinical trials through changes to eligibility criteria, enrolment practices, and trial designs....

Infographics